Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its wholly‑owned subsidiary, Xiamen Innovax Biotech Co., Ltd., has received the Drug Clinical Trial Approval Notice from China’s National Medical Products Administration (NMPA) for its Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), authorizing clinical trials for the prevention of lower respiratory tract disease (LRTD) caused by RSV infection in adults aged 60 and above.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Action | Drug Clinical Trial Approval Notice issued (domestic drug registration clinical trial) |
| Product | Lyophilized Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) |
| Notice No. | 2026LP03060 |
| Indication | Prevention of RSV‑caused lower respiratory tract disease in people aged 60+ |
| Dosage Form / Spec | Injection; 0.5 ml per human dose after reconstitution |
| Applicant | Xiamen Innovax Biotech – wholly‑owned subsidiary of Wantai Biological Pharmacy (SHA: 603392) |
| Filing History | Clinical trial application accepted 20 Jul 2026 (Announcement No. 2026‑036, disclosed 21 Jul 2026) |
| Legal Basis | Drug Administration Law and Vaccine Administration Law of the PRC |
Drug Profile & Mechanism of Action
- Modality: A recombinant protein RSV vaccine jointly developed by Xiamen Innovax and Xiamen University, produced via genetic engineering recombinant technology in CHOZN® cells.
- Active Component: An independently developed RSV pre‑fusion conformation membrane fusion protein F (pre‑F) – the antigen conformation that elicits the most potent RSV‑neutralizing antibody responses.
- Preclinical Evidence: Preclinical data show a favorable safety profile, with the vaccine inducing RSV‑specific protective immune responses in multiple animal models including mice and cotton rats – supporting its potential as a preferred solution for protecting elderly and immunocompromised populations against severe RSV lower respiratory infection.
- Adjuvant‑Free Lyophilized Design: The product is an adjuvant‑free lyophilized formulation – technically distinct from adjuvanted vaccines of the same class. Adjuvanted products produce more pronounced immune enhancement with rapid antibody rise; adjuvant‑free products feature simpler composition and gentler immune stimulation. The two routes address different clinical needs, each with its own suitability advantages.
Disease Background
- RSV Burden in the Elderly: RSV is a common respiratory pathogen; in susceptible groups such as the elderly and chronic‑disease patients, infection readily progresses to severe conditions including bronchiolitis and pneumonia.
- Domestic Treatment Gap: Currently in China, RSV infection can only be managed with broad‑spectrum antivirals combined with symptomatic support – there is no marketed recombinant RSV vaccine (CHO cell) domestically, underscoring the urgent clinical need for effective RSV vaccines.
Risk Factors Disclosed
- Development Uncertainty: Under China’s vaccine regulatory framework, an investigational vaccine must typically complete Phase I/II/III clinical trials, marketing authorization application and review, and GMP compliance inspection before market access. Vaccine development cycles are generally long – whether the lyophilized recombinant RSV vaccine (CHO cell) succeeds in R&D and obtains domestic marketing approval remains uncertain.
- Competitive Landscape: Although no recombinant RSV vaccine (CHO cell) has been marketed in China, multiple competing products have entered clinical trials or registration review. Even upon successful launch, the product will face substantial competitive pressure and uncertainty from evolving market conditions.
Market Impact & Outlook
- Elderly RSV Vaccination Market: With China’s rapidly aging population and RSV increasingly recognized as a major cause of lower respiratory hospitalization in older adults, an indigenous pre‑F protein vaccine for the 60+ population targets a large, underserved preventive‑care market.
- Differentiated Adjuvant‑Free Route: The adjuvant‑free lyophilized design offers a gentler immunogenicity profile that may suit frail elderly recipients – a deliberate differentiation from the adjuvanted RSV vaccines dominating global markets.
- Wantai Vaccine Franchise Extension: The approval adds an RSV program to Wantai/Innovax’s vaccine portfolio – building on the subsidiary’s established recombinant vaccine manufacturing base – and deepens the group’s presence in adult immunization.
- Academic‑Industry Synergy: Joint development with Xiamen University continues Wantai’s proven university‑partnership model for novel vaccine innovation.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial progression, regulatory approval and commercial potential of the lyophilized recombinant RSV vaccine (CHO cell). Actual results may differ materially due to risks including multi‑phase clinical trial outcomes, lengthy vaccine approval cycles, competitive entry by rival RSV candidates, and evolving NMPA requirements. Investors are advised to exercise caution.-Fineline Info & Tech
